# Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention

Study · id `cardio:ct-nct04937699` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04937699](<https://clinicaltrials.gov/study/NCT04937699>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04937699

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2690 participants.

## Technical summary

Registry record NCT04937699. Randomized; no masking; primary purpose treatment. Start 2023-03-28 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2690 participants (planned count; ClinicalTrials.gov record NCT04937699, source copy `cardio:ctgov-nct04937699-2024-08-07`, retrieved 2026-10-31)
- Started: 2023-03-28 (actual) (ClinicalTrials.gov record NCT04937699, source copy `cardio:ctgov-nct04937699-2024-08-07`, retrieved 2026-10-31)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT04937699, source copy `cardio:ctgov-nct04937699-2024-08-07`, retrieved 2026-10-31)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT04937699, source copy `cardio:ctgov-nct04937699-2024-08-07`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04937699, source copy `cardio:ctgov-nct04937699-2024-08-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04937699-2024-08-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
- Acronym: MATE
- Condition: Acute Coronary Syndrome
- Condition: Percutaneous Coronary Intervention
- Intervention (Drug): Standard-DAPT of Ticagrelor plus aspirin
- Intervention (Drug): Sequential monotherapy of Ticagrelor and clopidogrel
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: 4459547b1745c6f93f33221687c99a2960436768640e1be847c17fb94e663661
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
